Barclays researcher who left for buyside is back at Barclays
Dimiter Tassev has just rejoined Barclays after nearly ten years away from the firm – including stints at Citadel subsidiary Surveyor Capital, pharmaceutical company Merck, and - most recently - hedge fund ExodusPoint, where he was a portfolio manager. When he left Barclays back in 2014, Tassev was an (Assistant) Vice President biotech analyst. He's just returned to the bank as a director in the field.
Given that Tassev was a portfolio manager at ExodusPoint before leaving, it might seem like an odd career move. But on one hand, whilst a lot of portfolio managers enjoy life, others… Do not. Even though well-paid, the role can be deeply toxic, with the stakes absurdly high and mistakes punished for a long, long time. With healthcare going against the market for 2023, it might not be surprising that managing a portfolio in the industry might be… Tumultuous.
Have a confidential story, tip, or comment you’d like to share? Contact: +44 7537 182250 (SMS, Whatsapp or voicemail). Telegram: @SarahButcher. Click here to fill in our anonymous form, or email email@example.com. Signal also available.
Bear with us if you leave a comment at the bottom of this article: all our comments are moderated by human beings. Sometimes these humans might be asleep, or away from their desks, so it may take a while for your comment to appear. Eventually it will – unless it’s offensive or libelous (in which case it won’t.)